{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T14:14:47Z","timestamp":1772806487158,"version":"3.50.1"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antibody testing is commonly used to assess past exposure to pathogens, but the interpretation is complex. We quantified test-specific SARS-CoV-2 seroconversion and seroreversion by time since PCR-confirmed infection, age and disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We combined Belgian data from laboratory SARS-CoV-2 testing, prescriptions, contact tracing and hospital surveillance collected between March 2020 and June 2021 with data from published longitudinal studies on Wantai and EuroImmun IgG serological tests.<\/jats:p>\n                    <jats:p>We used a hierarchical Bayesian model to estimate time-varying sensitivity of serological tests following PCR-confirmed infection. The model employed a scaled Weibull-bi-exponential distribution. We accounted for disease severity (distinguishing between asymptomatic, symptomatic, and hospitalized cases), age (i.e., age groups 18\u201349, 50\u201364, and 65\u201374 years) and serological test used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 44,262 serological test results: 10,864 obtained from published studies, 33,398 from Belgian laboratories. Seroconversion occurred during the six weeks following a PCR-confirmed infection. Age, disease severity and the test used strongly influenced seroconversion rates and the rate of the subsequent seroreversion. For the EuroImmun test, 82% (95% Credible Interval (CrI): 80%\u221284%) of symptomatic individuals in the youngest age group seroconverted, compared to 95% (CrI: 95%\u221296%) for the Wantai test. Seroconversion was associated with hospitalization, (OR = 8.17 (CrI: 5.56\u201313.72), compared to asymptomatic infection) and older age (OR = 1.65 (CrI: 1.41\u20131.97), compared to 18\u201349 year-olds). Slower seroreversion was associated with older age, hospitalization and the Wantai test. At 50 weeks, seropositivity among symptomatic 18\u201349 year-olds was 64% (CrI: 58%\u221270%) for the EuroImmun test and 95% (CrI: 94%\u221296%) for the Wantai test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings highlight the need for test-specific, time-varying sensitivity adjustments in seroprevalence studies. Such adjustments are crucial for translating seroprevalence results to cumulative incidence estimates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0328144","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:35:07Z","timestamp":1770057307000},"page":"e0328144","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Factors influencing SARS-CoV-2 IgG test sensitivity: A Bayesian analysis of seroconversion and seroreversion by time since infection, test, age and disease severity"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-4613","authenticated-orcid":true,"given":"Toon","family":"Braeye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"11","key":"pone.0328144.ref001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004107","article-title":"Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies","volume":"19","author":"I Bergeri","year":"2022","journal-title":"PLoS Med"},{"key":"pone.0328144.ref002","doi-asserted-by":"crossref","first-page":"108814","DOI":"10.1016\/j.clim.2021.108814","article-title":"Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection","volume":"230","author":"P Dehghani-Mobaraki","year":"2021","journal-title":"Clin Immunol"},{"issue":"21","key":"pone.0328144.ref003","doi-asserted-by":"crossref","first-page":"2200809","DOI":"10.2807\/1560-7917.ES.2023.28.21.2200809","article-title":"Dynamics of SARS-CoV-2 seroassay sensitivity: a systematic review and modelling study","volume":"28","author":"N Owusu-Boaitey","year":"2023","journal-title":"Euro Surveill"},{"issue":"11","key":"pone.0328144.ref004","article-title":"Antibody tests for identification of current and past infection with SARS-CoV-2","volume":"11","author":"T Fox","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"pone.0328144.ref005","doi-asserted-by":"crossref","first-page":"100168","DOI":"10.1016\/j.jcvp.2023.100168","article-title":"Comparative evaluation of SARS-CoV-2 serological tests shows significant variability in performance across different years of infection and between the tests","volume":"3","author":"D-D Kenfack","year":"2023","journal-title":"J Clin Virol Plus"},{"issue":"6","key":"pone.0328144.ref006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252317","article-title":"Performance of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies in South Africa","volume":"16","author":"MP Gededzha","year":"2021","journal-title":"PLoS One"},{"issue":"18","key":"pone.0328144.ref007","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral Immune Response to SARS-CoV-2 in Iceland","volume":"383","author":"DF Gudbjartsson","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0328144.ref008","article-title":"Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis","volume":"370","author":"M Lisboa Bastos","year":"2020","journal-title":"BMJ"},{"key":"pone.0328144.ref009","doi-asserted-by":"crossref","first-page":"103561","DOI":"10.1016\/j.ebiom.2021.103561","article-title":"Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection","volume":"71","author":"F Gallais","year":"2021","journal-title":"EBioMedicine"},{"issue":"3","key":"pone.0328144.ref010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Y Yang","year":"2022","journal-title":"Nat Microbiol"},{"issue":"3","key":"pone.0328144.ref011","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/infdis\/jiaa659","article-title":"Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients","volume":"223","author":"F Muecksch","year":"2021","journal-title":"J Infect Dis"},{"key":"pone.0328144.ref012","doi-asserted-by":"crossref","first-page":"105052","DOI":"10.1016\/j.jcv.2021.105052","article-title":"Antibody response to SARS-CoV-2 for more than one year \u2212 kinetics and persistence of detection are predominantly determined by avidity progression and test design","volume":"146","author":"H Scheiblauer","year":"2022","journal-title":"J Clin Virol"},{"key":"pone.0328144.ref013","doi-asserted-by":"crossref","first-page":"103259","DOI":"10.1016\/j.ebiom.2021.103259","article-title":"Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS\u2011CoV-2 infection","volume":"65","author":"C Manisty","year":"2021","journal-title":"EBioMedicine"},{"issue":"7","key":"pone.0328144.ref014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288557","article-title":"Kinetics of specific anti-SARS-CoV-2 IgM, IgA, and IgG responses during the first 12 months after SARS-CoV-2 infection: A prospective longitudinal study","volume":"18","author":"H Amellal","year":"2023","journal-title":"PLOS ONE"},{"key":"pone.0328144.ref015","doi-asserted-by":"crossref","first-page":"750448","DOI":"10.3389\/fimmu.2021.750448","article-title":"Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4+ T-Cell Responses","volume":"12","author":"E Marklund","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"pone.0328144.ref016","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1093\/aje\/kwae125","article-title":"SARS-CoV-2 incidence, seroprevalence, and antibody dynamics in a rural, population-based cohort: March 2020-July 2022","volume":"194","author":"JG Petrie","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pone.0328144.ref017","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/aje\/kwaf157","article-title":"The impact of statistical adjustment for assay performance on inferences from SARS-CoV-2 serological surveillance studies","volume":"194","author":"J Chen","year":"2025","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pone.0328144.ref018","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41467-020-20247-4","article-title":"Neutralizing antibody titres in SARS-CoV-2 infections","volume":"12","author":"EHY Lau","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"pone.0328144.ref019","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1186\/s12879-021-06517-6","article-title":"Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership","volume":"21","author":"DM Herrington","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"11","key":"pone.0328144.ref020","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid decay of anti\u2013SARS-CoV-2 antibodies in persons with mild Covid-19","volume":"383","author":"FJ Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"pone.0328144.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244126","article-title":"Antibody response to SARS-CoV-2 infection in humans: A systematic review","volume":"15","author":"N Post","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"pone.0328144.ref022","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"K Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"1","key":"pone.0328144.ref023","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/joim.13560","article-title":"Factors influencing the immune response over 15 months after SARS-CoV-2 infection: A longitudinal population-wide study in the Faroe Islands","volume":"293","author":"MS Petersen","year":"2023","journal-title":"J Intern Med"},{"issue":"7","key":"pone.0328144.ref024","article-title":"SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants","volume":"18","author":"F Tea","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"pone.0328144.ref025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","article-title":"Estimating prevalence from the results of a screening test","volume":"107","author":"WJ Rogan","year":"1978","journal-title":"Am J Epidemiol"},{"issue":"11","key":"pone.0328144.ref026","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064240","article-title":"Systematic review of seroprevalence of SARS-CoV-2 antibodies and appraisal of evidence, prior to the widespread introduction of vaccine programmes in the WHO European Region, January-December 2020","volume":"13","author":"A Vaughan","year":"2023","journal-title":"BMJ Open"},{"issue":"1","key":"pone.0328144.ref027","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13690-020-00505-z","article-title":"Rapid establishment of a national surveillance of COVID-19 hospitalizations in Belgium","volume":"78","author":"N Van Goethem","year":"2020","journal-title":"Arch Public Health"},{"key":"pone.0328144.ref028","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijid.2022.01.041","article-title":"Long-term detection of SARS-CoV-2 antibodies after infection and risk of re-infection","volume":"116","author":"BL H\u00f8nge","year":"2022","journal-title":"Int J Infect Dis"},{"issue":"9","key":"pone.0328144.ref029","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/aje\/kwad106","article-title":"SARS-CoV-2 Serology Across Scales: A Framework for Unbiased Estimation of Cumulative Incidence Incorporating Antibody Kinetics and Epidemic Recency","volume":"192","author":"S Takahashi","year":"2023","journal-title":"Am J Epidemiol"},{"key":"pone.0328144.ref030","doi-asserted-by":"crossref","first-page":"19492","DOI":"10.1038\/s41598-022-23821-6","article-title":"Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020","volume":"12","author":"H Neuhauser","year":"2022","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0328144.ref031","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1186\/s12889-022-13694-9","article-title":"Disability adjusted life years associated with COVID-19 in Denmark in the first year of the pandemic","volume":"22","author":"SM Pires","year":"2022","journal-title":"BMC Public Health"},{"issue":"6","key":"pone.0328144.ref032","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252617","article-title":"Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis","volume":"16","author":"N Bobrovitz","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"pone.0328144.ref033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00100-z","article-title":"German federal-state-wide seroprevalence study of 1st SARS-CoV-2 pandemic wave shows importance of long-term antibody test performance","volume":"2","author":"S Lohse","year":"2022","journal-title":"Commun Med"},{"issue":"5","key":"pone.0328144.ref034","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/aje\/kwad226","article-title":"Correcting for antibody waning in cumulative incidence estimation from sequential serosurveys","volume":"193","author":"S Kadelka","year":"2024","journal-title":"Am J Epidemiol"},{"issue":"1","key":"pone.0328144.ref035","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02314-22","article-title":"Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference","volume":"11","author":"M Graninger","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"10","key":"pone.0328144.ref036","doi-asserted-by":"crossref","first-page":"001653","DOI":"10.1099\/jgv.0.001653","article-title":"Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2","volume":"102","author":"L Olbrich","year":"2021","journal-title":"J Gen Virol"},{"issue":"1","key":"pone.0328144.ref037","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac020","article-title":"Trend in sensitivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology one year after mild and asymptomatic coronavirus disease 2019 (COVID-19): unpacking potential bias in seroprevalence studies","volume":"75","author":"CR Bailie","year":"2022","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0328144.ref038","doi-asserted-by":"crossref","first-page":"106551","DOI":"10.1016\/j.actatropica.2022.106551","article-title":"Seroprevalence of SARS-CoV-2 on health professionals via Bayesian estimation: a Brazilian case study before and after vaccines","volume":"233","author":"CBS Maior","year":"2022","journal-title":"Acta Trop"},{"issue":"8","key":"pone.0328144.ref039","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.3390\/microorganisms11081985","article-title":"Comparative longitudinal serological study of anti-SARS-CoV-2 antibody profiles in people with COVID-19","volume":"11","author":"MH Barrios","year":"2023","journal-title":"Microorganisms"},{"issue":"11","key":"pone.0328144.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.06.040","article-title":"Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance","volume":"27","author":"J Perez-Saez","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"pone.0328144.ref041","article-title":"SerumCovid database: Description and preliminary analysis of serological COVID-19 diagnosis in healthcare workers","volume":"17","author":"ID Lins","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"pone.0328144.ref042","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/jalm\/jfab173","article-title":"Long-Term Comparison of 7 SARS-CoV-2 Antibody Assays in the North Zealand Covid-19 Cohort","volume":"7","author":"EF Wiwe","year":"2022","journal-title":"J Appl Lab Med"},{"issue":"6","key":"pone.0328144.ref043","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-048142","article-title":"Evaluation of the IgG antibody response to SARS CoV-2 infection and performance of a lateral flow immunoassay: cross-sectional and longitudinal analysis over 11 months","volume":"11","author":"LJ Robertson","year":"2021","journal-title":"BMJ Open"},{"key":"pone.0328144.ref044","article-title":"Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications","author":"F Wu","year":"2020","journal-title":"medRxiv"},{"issue":"6","key":"pone.0328144.ref045","article-title":"Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study","volume":"2","author":"WN Chia","year":"2021","journal-title":"Lancet Microbe"},{"issue":"9","key":"pone.0328144.ref046","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa1685","article-title":"Lack of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in a Large Cohort of Previously Infected Persons","volume":"73","author":"LR Petersen","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"31","key":"pone.0328144.ref047","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3409","article-title":"SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay","volume":"7","author":"MJ Peluso","year":"2021","journal-title":"Sci Adv"},{"issue":"3","key":"pone.0328144.ref048","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciab004","article-title":"The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers","volume":"73","author":"SF Lumley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0328144.ref049","doi-asserted-by":"crossref","first-page":"13491","DOI":"10.1038\/s41598-022-17605-1","article-title":"Kinetics of neutralizing antibodies against SARS-CoV-2 infection according to sex, age, and disease severity","volume":"12","author":"Y Kim","year":"2022","journal-title":"Sci Rep"},{"issue":"2","key":"pone.0328144.ref050","doi-asserted-by":"crossref","first-page":"100523","DOI":"10.1016\/j.xcrm.2022.100523","article-title":"Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection","volume":"3","author":"E Pradenas","year":"2022","journal-title":"Cell Rep Med"},{"issue":"2","key":"pone.0328144.ref051","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00072-23","article-title":"Testing for SARS-CoV-2: lessons learned and current use cases","volume":"37","author":"ES Theel","year":"2024","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"pone.0328144.ref052","article-title":"Association of Age With SARS-CoV-2 Antibody Response","volume":"4","author":"HS Yang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"pone.0328144.ref053","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijid.2021.07.027","article-title":"Age significantly influences the sensitivity of SARS-CoV-2 rapid antibody assays","volume":"109","author":"N Irwin","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0328144.ref054","doi-asserted-by":"crossref","first-page":"13417","DOI":"10.1038\/s41598-024-64414-9","article-title":"Tracking the evolution of anti-SARS-CoV-2 antibodies and long-term humoral immunity within 2 years after COVID-19 infection","volume":"14","author":"M Movsisyan","year":"2024","journal-title":"Sci Rep"},{"issue":"11","key":"pone.0328144.ref055","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01138-21","article-title":"The Fall in Antibody Response to SARS-CoV-2: a Longitudinal Study of Asymptomatic to Critically Ill Patients Up to 10 Months after Recovery","volume":"59","author":"M Peghin","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"2","key":"pone.0328144.ref056","doi-asserted-by":"crossref","first-page":"2149732","DOI":"10.1080\/13814788.2022.2149732","article-title":"Prevalence of SARS-CoV-2 antibodies among Belgian nursing home residents and staff during the primary COVID-19 vaccination campaign","volume":"29","author":"E Meyers","year":"2023","journal-title":"Eur J Gen Pract"},{"issue":"4","key":"pone.0328144.ref057","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/EDE.0000000000001361","article-title":"Estimating the Cumulative Incidence of SARS-CoV-2 Infection and the Infection Fatality Ratio in Light of Waning Antibodies","volume":"32","author":"K Shioda","year":"2021","journal-title":"Epidemiology"},{"issue":"1","key":"pone.0328144.ref058","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00106-7","article-title":"Estimating the COVID-19 infection fatality ratio accounting for seroreversion using statistical modelling","volume":"2","author":"NF Brazeau","year":"2022","journal-title":"Commun Med"},{"issue":"6526","key":"pone.0328144.ref059","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1126\/science.abe9728","article-title":"Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic","volume":"371","author":"LF Buss","year":"2021","journal-title":"Science"},{"issue":"1","key":"pone.0328144.ref060","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1186\/s12889-023-17239-6","article-title":"Riding high: seroprevalence of SARS-CoV-2 after 4 pandemic waves in Manitoba, Canada, April 2020\u2013February 2022","volume":"23","author":"S Duong","year":"2023","journal-title":"BMC Public Health"},{"issue":"10344","key":"pone.0328144.ref061","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1016\/S0140-6736(22)00484-6","article-title":"Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis","volume":"399","author":"RM Barber","year":"2022","journal-title":"The Lancet"},{"issue":"3","key":"pone.0328144.ref062","first-page":"147","article-title":"SARS-CoV-2 viral load and shedding kinetics","volume":"21","author":"O Puhach","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"pone.0328144.ref063","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/jech-2023-220569","article-title":"Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study","volume":"78","author":"J Be\u0161evi\u0107","year":"2024","journal-title":"J Epidemiol Community Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:35:18Z","timestamp":1770057318000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0328144"}},"subtitle":[],"editor":[{"given":"Caio Bezerra Souto","family":"Maior","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":63,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0328144","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]}}}